AP2004002998A0 - Intraorally disintegrating valdecoxib compositions - Google Patents

Intraorally disintegrating valdecoxib compositions

Info

Publication number
AP2004002998A0
AP2004002998A0 APAP/P/2004/002998A AP2004002998A AP2004002998A0 AP 2004002998 A0 AP2004002998 A0 AP 2004002998A0 AP 2004002998 A AP2004002998 A AP 2004002998A AP 2004002998 A0 AP2004002998 A0 AP 2004002998A0
Authority
AP
ARIPO
Prior art keywords
compositions
intraorally disintegrating
valdecoxib compositions
disintegrating valdecoxib
intraorally
Prior art date
Application number
APAP/P/2004/002998A
Other languages
English (en)
Inventor
Trang T Le
Blake Ludwig
Joseph P Reo
Uday J Shah
Ken Yamamoto
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AP2004002998A0 publication Critical patent/AP2004002998A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/2004/002998A 2001-09-26 2002-09-23 Intraorally disintegrating valdecoxib compositions AP2004002998A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26
PCT/US2002/030161 WO2003026623A1 (en) 2001-09-26 2002-09-23 Intraorally disintegrating valdecoxib compositions

Publications (1)

Publication Number Publication Date
AP2004002998A0 true AP2004002998A0 (en) 2004-03-31

Family

ID=23267542

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2004/002998A AP2004002998A0 (en) 2001-09-26 2002-09-23 Intraorally disintegrating valdecoxib compositions
APAP/P/2004/002999A AP2004002999A0 (en) 2001-09-26 2002-09-23 Organoleptically acceptable intraorally disintegrating compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/002999A AP2004002999A0 (en) 2001-09-26 2002-09-23 Organoleptically acceptable intraorally disintegrating compositions

Country Status (25)

Country Link
US (1) US20030181501A1 (enExample)
EP (2) EP1429736A2 (enExample)
JP (2) JP2005506987A (enExample)
KR (2) KR20040044990A (enExample)
CN (2) CN1633281A (enExample)
AP (2) AP2004002998A0 (enExample)
AR (1) AR037239A1 (enExample)
BR (2) BR0212778A (enExample)
CA (2) CA2461044A1 (enExample)
CO (2) CO5570684A2 (enExample)
EA (2) EA200400357A1 (enExample)
EC (1) ECSP045029A (enExample)
GE (1) GEP20063856B (enExample)
HK (1) HK1079988A1 (enExample)
IL (2) IL160855A0 (enExample)
IS (2) IS7178A (enExample)
MA (2) MA27682A1 (enExample)
MX (2) MXPA04002652A (enExample)
NO (2) NO20041258L (enExample)
OA (2) OA13060A (enExample)
PL (2) PL369297A1 (enExample)
TN (2) TNSN04045A1 (enExample)
WO (2) WO2003026697A2 (enExample)
YU (1) YU34804A (enExample)
ZA (2) ZA200401953B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
WO2006016602A1 (ja) * 2004-08-10 2006-02-16 Ajinomoto Co., Inc. 苦味の低減したナテグリニド含有製剤
WO2006070845A1 (ja) * 2004-12-28 2006-07-06 Eisai R & D Management Co., Ltd. 速崩壊性錠剤及びその製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
KR20080080318A (ko) * 2005-12-20 2008-09-03 에자이 알앤드디 매니지먼트 가부시키가이샤 지용성 약물을 함유하는 구강내 속붕정
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
WO2007142811A2 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
KR20100033400A (ko) * 2007-06-06 2010-03-29 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
EP2164461B1 (de) * 2007-06-06 2013-01-23 Basf Se Kau- und lutsch-tabletten
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
ES2534433T3 (es) * 2007-08-07 2015-04-22 Acelrx Pharmaceuticals, Inc. Composiciones que comprenden sufentanilo y triazolam para sedación y analgesia operatorias utilizando formas farmacéuticas transmucosas orales
US20110086070A1 (en) * 2008-03-24 2011-04-14 Munish Talwar Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2368544A4 (en) * 2008-11-25 2012-08-15 Mitsubishi Tanabe Pharma Corp RASCH IN MOUTH DAMAGING TABLET AND METHOD FOR THEIR MANUFACTURE
CA2765033C (en) 2009-06-12 2020-07-14 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) * 1995-06-13 1997-04-09 American Home Prod Organoleptically acceptable oral pharmaceutical compositions
DK0855988T3 (da) * 1995-10-20 2002-08-19 Upjohn Co Blisterpakning
CZ291463B6 (cs) * 1996-05-17 2003-03-12 Merck And Co., Inc. Farmaceutický prostředek
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
WO2001041761A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
DE60120710T2 (de) * 2000-08-18 2007-06-14 Pharmacia Corp. Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
ZA200402364B (en) 2005-01-13
KR20040044990A (ko) 2004-05-31
YU34804A (sh) 2006-08-17
BR0212778A (pt) 2004-12-07
CA2461630A1 (en) 2003-04-03
CO5570684A2 (es) 2005-10-31
PL369298A1 (en) 2005-04-18
WO2003026697A3 (en) 2003-07-03
JP2005506987A (ja) 2005-03-10
KR20040058189A (ko) 2004-07-03
WO2003026697A2 (en) 2003-04-03
MA27682A1 (fr) 2006-01-02
AR037239A1 (es) 2004-11-03
EP1429736A2 (en) 2004-06-23
MA27542A1 (fr) 2005-10-03
GEP20063856B (en) 2006-06-26
JP2005512964A (ja) 2005-05-12
AP2004002999A0 (en) 2004-03-31
WO2003026623A8 (en) 2004-09-30
HK1079988A1 (zh) 2006-04-21
OA12707A (en) 2006-06-26
US20030181501A1 (en) 2003-09-25
CN1633281A (zh) 2005-06-29
NO20041258L (no) 2003-03-27
EA200400357A1 (ru) 2004-08-26
CO5570659A2 (es) 2005-10-31
IL160855A0 (en) 2004-08-31
EA200400352A1 (ru) 2004-12-30
ECSP045029A (es) 2004-04-28
BR0212861A (pt) 2004-10-05
IS7178A (is) 2004-03-11
OA13060A (en) 2006-11-10
IS7177A (is) 2004-03-11
TNSN04045A1 (fr) 2006-06-01
CA2461044A1 (en) 2003-04-03
MXPA04002798A (es) 2004-07-05
WO2003026623A1 (en) 2003-04-03
CN1703203A (zh) 2005-11-30
IL160848A0 (en) 2004-08-31
TNSN04047A1 (fr) 2006-06-01
PL369297A1 (en) 2005-04-18
MXPA04002652A (es) 2004-06-07
NO20041532L (no) 2004-04-15
EP1490035A1 (en) 2004-12-29
ZA200401953B (en) 2005-05-09

Similar Documents

Publication Publication Date Title
AP2004002998A0 (en) Intraorally disintegrating valdecoxib compositions
MXPA02006151A (es) Composiciones de liberacion dual de un inhibidor de ciclooxigenasa-2.
UA58576C2 (uk) Фармацевтична композиція, що містить целекоксиб
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
AU2003296993A8 (en) Cyclopropyl compounds as ccr5 antagonists
WO2001041762A3 (en) Valdecoxib compositions
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
NO976048L (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
AU2003297048A8 (en) Cyclohexyl compounds as ccr5 antagonists
TW200510416A (en) P38 inhibitors and methods of use thereof
AU2003296992A1 (en) Pyrrolidine and azetidine compounds as ccr5 antagonists
PL1635824T3 (pl) 5-Członowe heterocykliczne inhibitory P-38
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
NO20056161L (no) Formuleringer for behandling av artrittilstander
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
YU37104A (sh) Preparati valdekoksiba sa oralnim razlaganjem dobijeni postupkom sušenja raspršivanjem
MXPA04004290A (es) Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
DE60212130D1 (en) Carvedilolpolymorph
MD2228G2 (ro) Utilizarea derivaţiilor izotiouronici în tratamentul şi profilaxia atoniei intestinale
TNSN05307A1 (en) 5-membered heterocycle-based p38 kinase inhibitors